Second quarter 2026
Filed Aug 12, 2026AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
AEON advanced ABP-450 analytical and regulatory activities and completed a financing expected to fund operations into the first quarter of 2027, but reported a $5,919 thousand loss from operations, had $3,431 thousand of cash and cash equivalents at June 30, 2026 before the July offering, and remained in a stockholders' deficit position.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Selling, general and administrativeGAAP | $2,991 | – | – |
| Research and developmentGAAP | $2,938 | – | – |
| Change in fair value of contingent considerationGAAP | $(10) | – | – |
| Total operating costs and expensesGAAP | $5,919 | – | – |
| Loss from operationsGAAP | $(5,919) | – | – |
| Change in fair value of convertible notesGAAP | $(213) | – | – |
| Change in fair value of warrantsGAAP | $4,941 | – | – |
| Cash and cash equivalentsother | $3,431 | – | – |
| Convertible notes at fair value, including related party amount of $1,755 and $34,600 at June 30, 2026 and December 31, 2025, respectivelyother | $1,755 | – | – |
| Warrant liabilitiesother | $11,367 | – | – |
| Total liabilitiesother | $21,271 | – | – |
| Total stockholders' deficitother | $(15,361) | – | – |
Second half of 2026 and first quarter of 2027 outlook
- NoteCash and cash equivalents are expected to fund operations into the first quarter of 2027.
- NoteSecond half 2026: Receipt of additional FDA feedback expected to inform the next phase of the ABP-450 biosimilar development program, including clinical pharmacology and comparative clinical study requirements.
What drove it
- AEON continued the analytical phase of its ABP-450 biosimilar development program.
- The Company stated that FDA feedback from its BPD Type 2a meeting supported its planned analytical development approach for ABP-450.
- AEON expects a planned BPD Type 2b interaction in the second half of 2026 to help inform clinical pharmacology and comparative clinical study requirements.
- The Company presented data supporting analytical similarity to BOTOX® at the 2026 American Academy of Neurology Annual Meeting and the American Headache Society Annual Meeting.
- On August 3, 2026, the Company regained full compliance with NYSE American continued listing requirements.
Concerns
- Loss from operations was $(5,919) for the three months ended June 30, 2026.
- Research and development expense was $2,938 for the three months ended June 30, 2026, compared with $1,064 for the three months ended June 30, 2025.
- Cash and cash equivalents were $3,431 at June 30, 2026 and did not include the approximately $13.6 million of net proceeds from the July 2026 underwritten public offering.
- Additional financing beyond the stated runway and the potential cash exercise of milestone warrants remain relevant to funding the development program.
- The next development phase remains dependent on expected FDA feedback concerning clinical pharmacology and comparative clinical study requirements.
What to watch
- Receipt of additional FDA feedback in the second half of 2026.
- The clinical pharmacology and comparative clinical study requirements that follow the planned BPD Type 2b interaction.
- The Company's execution against its stated cash runway into the first quarter of 2027.
- Potential gross proceeds upon cash exercise of the milestone warrants.
- Continued maintenance of NYSE American listing compliance.
Balance sheet and cash flow
- Cash and cash equivalents were $3,431 as of June 30, 2026.
- In July 2026, the Company completed an underwritten public offering that included net upfront proceeds of approximately $13.6 million.
- The financing included up to an additional $34.0 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.
- Total liabilities were $21,271 at June 30, 2026, including $1,755 of convertible notes at fair value and $11,367 of warrant liabilities.
- Total stockholders' deficit was $(15,361) at June 30, 2026.
Analysis
AEON's quarter centered on advancing ABP-450 rather than commercial execution. The Company reported that its first-quarter BPD Type 2a meeting with the FDA supported its planned analytical development approach under the 351(k) biosimilar pathway. Management is now seeking further FDA feedback in the second half of 2026 that is expected to inform clinical pharmacology and comparative clinical study requirements.
The reported expense base reflects this development focus. Research and development expense was $2,938 for the three months ended June 30, 2026, compared with $1,064 for the three months ended June 30, 2025. Selling, general and administrative expense was $2,991, compared with $3,258 in the prior-year period. Total operating costs and expenses were $5,919, producing a loss from operations of $(5,919), versus $(4,338) in the prior-year period.
Liquidity improved after period end through the July underwritten public offering. Cash and cash equivalents were $3,431 at June 30, 2026, while the Company said the July offering generated net upfront proceeds of approximately $13.6 million. The offering also included milestone warrants that could provide up to an additional $34.0 million in potential gross proceeds upon full cash exercise. The Company expects cash and cash equivalents, including the offering proceeds, to fund operations into the first quarter of 2027.
The balance sheet still requires attention. At June 30, 2026, AEON reported total liabilities of $21,271, warrant liabilities of $11,367, and total stockholders' deficit of $(15,361). The quarter also included a $4,941 change in fair value of warrants and a $(213) change in fair value of convertible notes, both of which affect reported results but are separate from operating costs.
The principal near-term catalyst is regulatory rather than financial guidance. AEON plans to obtain additional FDA feedback in the second half of 2026, with the stated objective of defining the next development requirements for ABP-450. The company also regained full compliance with NYSE American continued listing requirements on August 3, 2026, removing the previously identified listing deficiencies cited in the release.
Management, verbatim
The second quarter marked continued progress in advancing ABP-450 through the analytical phase of our biosimilar development program while also strengthening the Company's financial position.
Rob Bancroft, President and Chief Executive Officer of AEON
As we enter the second half of 2026, our primary focus is obtaining FDA feedback on the next phase of development, including the clinical pharmacology and comparative clinical study requirements for ABP-450.
Rob Bancroft, President and Chief Executive Officer of AEON
Not in the filing
stated, not guessed- Total revenue was not reported in the supplied filing text.
- Segment revenue and segment operating metrics were not reported.
- Gross profit and gross margin were not reported.
- Net loss or net income, income tax expense or benefit, and tax rate are unavailable because the supplied statement of operations text ends after the beginning of the 'Other income, ne' line.
- Basic and diluted earnings per share were not provided in the supplied filing text.
- Non-GAAP financial measures were not reported.
- Operating cash flow, capital expenditures, and free cash flow were not reported.
- Share repurchases and dividends were not reported.
- Prior-quarter comparisons for reported quarterly metrics were not provided.
- Percentage year-over-year and quarter-over-quarter changes for reported metrics were not provided.
- Revenue, gross-margin, operating-expense, and tax-rate guidance were not provided.
- Previous-quarter outlook was not provided, so no comparison with prior guidance is available.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.